Cambridge, MA (PRWEB) July 22, 2010

Merrimack Pharmaceuticals, Inc. and sanofi-aventis declared these days that the 1st affected person has obtained an original dose in a Phase 2 randomized double blind clinical research combining MM-121 with exemestane (Aromasin